GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocera Therapeutics Inc (NAS:OCRX) » Definitions » EPS without NRI

Ocera Therapeutics (Ocera Therapeutics) EPS without NRI : $-0.96 (TTM As of Sep. 2017)


View and export this data going back to 2011. Start your Free Trial

What is Ocera Therapeutics EPS without NRI?

Ocera Therapeutics's earnings per share without non-recurring items for the three months ended in Sep. 2017 was $-0.24. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2017 was $-0.96.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Ocera Therapeutics's EPS without NRI or its related term are showing as below:

OCRX's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 4.95
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Ocera Therapeutics's EPS (Diluted) for the three months ended in Sep. 2017 was $-0.24. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2017 was $-0.96.

Ocera Therapeutics's EPS (Basic) for the three months ended in Sep. 2017 was $-0.24. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2017 was $-0.96.


Ocera Therapeutics EPS without NRI Historical Data

The historical data trend for Ocera Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocera Therapeutics EPS without NRI Chart

Ocera Therapeutics Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
EPS without NRI
Get a 7-Day Free Trial Premium Member Only -5.76 -2.52 -1.41 -1.33 -1.22

Ocera Therapeutics Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.32 -0.21 -0.28 -0.23 -0.24

Competitive Comparison of Ocera Therapeutics's EPS without NRI

For the Biotechnology subindustry, Ocera Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocera Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocera Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Ocera Therapeutics's PE Ratio without NRI falls into.



Ocera Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocera Therapeutics  (NAS:OCRX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Ocera Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Ocera Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocera Therapeutics (Ocera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
525 University Avenue, Suite 610, Palo Alto, CA, USA, 94301
Ocera Therapeutics Inc is a clinical-stage biopharmaceutical company, which primarily targets acute and chronic orphan liver diseases. The company is focused on the development and commercialization of a clinical product candidate, OCR-002 for the treatment of acute and chronic hepatic encephalopathy for patients with a serious complication of liver cirrhosis, or liver failure, marked by mental changes including confusion, impaired motor skills, disorientation in time and space, and, in its more severe form, stupor, coma and even death. All the business activity of the firm is functioned through the region of US.
Executives
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Steven P James director C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Nina S Kjellson director C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Domain Partners Viii, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Dp Viii Associates, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber director C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Kim P. Kamdar 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Brian K Halak 10 percent owner C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Dp Vi Associates, L.p. 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Associates Domain 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Domain Partners Vi, L.p. 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Nicole Vitullo 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
James C Blair 10 percent owner 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Jesse I Treu 10 percent owner

Ocera Therapeutics (Ocera Therapeutics) Headlines

From GuruFocus

Top 3 Insider Buys of the Week

By Monica Wolfe Monica Wolfe 07-19-2013

Three Insider Buys at 52-Week Lows

By Monica Wolfe Monica Wolfe 07-22-2014